证券日报网讯1月23日，步长制药（603858）在互动平台回答投资者提问时表示，公司近两年已实现欧 洲市场出口布局，但主要通过合作形式进入欧亚经济联盟国家。2024年控股子公司泸州步长与俄罗斯 LANCET公司签署协议，授权注射用BC001在该区域的注册与商业化推广，同时公司多款中药产品已销 往全球数十个国家及地区；对于欧盟核心国家，公司目前仍在推进主要产品的欧盟COS认证，后续销售 进展可关注公司专项回应及相关公告。 ...

Core Viewpoint - The company has established its export presence in the European market over the past two years, primarily through partnerships in the Eurasian Economic Union countries [1] Group 1: Market Expansion - In 2024, the company's subsidiary, Luzhou Buchang, will sign an agreement with Russia's LANCET company to authorize the registration and commercialization of injectable BC001 in the region [1] - The company has successfully sold multiple traditional Chinese medicine products to dozens of countries and regions worldwide [1] Group 2: Regulatory Progress - The company is currently advancing the EU COS certification for its main products in core EU countries, with future sales progress to be monitored through special responses and related announcements [1]